Biocompatible nanoscale contrast agents for MRI and CT scans: current progress and clinical potential

Conventional contrast agents for magnetic resonance imaging (MRI) and computed tomography (CT) have long served as the backbone of diagnostic imaging. Yet, their well-recognized limitations, including nephrogenic systemic fibrosis and progressive gadolinium deposition with Gd-based chelates, contrast-induced nephropathy with iodinated agents, and serious hypersensitivity reactions with approved iron oxide formulations, continue to drive the search for safer alternatives. Nanoparticle-based contrast agents (NCAs) have emerged as a compelling next generation of imaging tools, offering a degree of rational design simply not achievable with small-molecule agents. By independently tuning core composition, hydrodynamic size, surface chemistry, and morphology, NCAs can be engineered to enhance relaxivity or X-ray attenuation, extend vascular residence time, direct clearance toward renal or hepatobiliary pathways, and carry targeting ligands for site-specific delivery. This review covers the principal NCA classes, iron oxide nanoparticles, gadolinium- and manganese-based nanomaterials, gold and copper nanostructures, carbon dots, lanthanide-doped upconversion nanocrystals, and quantum dots, examining their physicochemical design, pharmacokinetics, biocompatibility, and diagnostic performance across oncological and vascular applications. A recurring theme is the central role of size: Particles below the ≈6 nm glomerular filtration threshold undergo renal excretion and exhibit lower bioaccumulation risk, while larger formulations follow hepatobiliary routes with implications for long-term tissue retention. Surface coating, protein corona formation, and mononuclear phagocyte system recognition are discussed as equally decisive determinants of in vivo behavior, often outweighing core composition in their influence on clearance and tolerability. Across material classes, preclinical evidence consistently shows favorable safety profiles for well-engineered NCAs, with minimal hemolysis, low immunogenicity, and absence of histological organ injury at imaging-relevant doses, a meaningful contrast to the adverse effect profiles of conventional agents. On the efficacy side, targeted NCA formulations have demonstrated promising results across multiple tumor types, including breast, brain, liver, lung, and renal cancers, with receptor-specific designs enabling molecular-level lesion characterization that conventional agents cannot provide. Multimodal and theranostic constructs, combining MRI or CT contrast with concurrent therapeutic function, further illustrate the flexibility that nanoparticulate platforms offer. Blood–brain barrier penetration for neurooncological applications and the emerging potential of magnetic particle imaging as a future translational direction for platforms based on superparamagnetic iron oxide nanoparticles are also discussed. The translational gap between preclinical promise and clinical reality remains the field’s most honest challenge, rooted in the scarcity of long-term human safety data, the lack of standardized preclinical evaluation frameworks, and the demanding requirements of good-manufacturing-practice production at scale. Addressing these gaps, through unified safety pipelines, harmonized reporting standards, and early-phase trials that connect imaging performance to clinical outcomes, is what will ultimately determine whether NCAs fulfill their considerable potential in diagnostic medicine.